Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 52.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,390,997 shares of the company's stock after selling 1,511,077 shares during the period. Invesco Ltd. owned approximately 1.13% of Guardant Health worth $42,495,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Guardant Health during the fourth quarter valued at $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman & Baird LLC bought a new position in Guardant Health during the fourth quarter valued at approximately $58,000. Quantbot Technologies LP purchased a new stake in Guardant Health in the fourth quarter worth approximately $80,000. Finally, Jones Financial Companies Lllp grew its position in Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after purchasing an additional 817 shares during the period. Hedge funds and other institutional investors own 92.60% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on GH shares. Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, February 24th. Stephens reiterated an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. Raymond James restated an "outperform" rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Piper Sandler lifted their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus upped their price objective on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $49.00.

Guardant Health Stock Down 0.5 %

GH stock traded down $0.21 during trading on Friday, hitting $44.97. The company had a trading volume of 1,843,910 shares, compared to its average volume of 2,140,122. The firm has a 50-day moving average price of $43.55 and a 200-day moving average price of $36.46. The firm has a market cap of $5.55 billion, a PE ratio of -12.63 and a beta of 1.45. Guardant Health, Inc. has a 1-year low of $16.77 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.